Ask AI
ProCE Banner Activity

A New Paradigm in IgAN Management: Expert Insights to Your Commonly Asked Questions

Clinical Thought

Learn about the latest advances in managing patients with IgA nephropathy (IgAN), strategies to determine when to refer to nephrology or clinical trials, and what questions remain unanswered regarding novel IgAN therapies.

Released: December 18, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education, in partnership with the American Kidney Fund (AKF).

ProCE Banner

Supporters

Supported by independent educational grants from Novartis Pharmaceuticals Corporation and Vertex Pharmaceuticals Incorporated.

Novartis Pharmaceuticals Corporation

Vertex Pharmaceuticals Incorporated

Partners

American Kidney Fund

ProCE Banner

Target Audience

This educational activity is intended for nephrology physicians, nurse practitioners, physician associates, and other healthcare professionals who care for patients with IgAN.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate the mechanistic targets of novel therapies for IgAN, including those that modulate the complement pathway, endothelin system, APRIL, and dual APRIL/BAFF signaling

  • Assess the most recent clinical efficacy and safety data on emerging IgAN therapies to support personalized treatment decisions

  • Implement patient-centered strategies incorporating novel IgAN treatments to slow disease progression and optimize long-term outcomes

Disclosure

Primary Author

Duvuru Geetha, MD: consultant/advisor/speaker: Amgen, Calliditas, GSK, Otsuka, Travere, Vera.